On May 1, 2025 Foresight Diagnostics, Inc. ("Foresight"), a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, reported that new data in newly diagnosed diffuse large B-cell lymphoma (DLBCL) will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from May 30 – June 3, 2025, in Chicago, Illinois (Press release, Foresight Diagnostics, MAY 1, 2025, View Source [SID1234652460]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will deliver an oral presentation in collaboration with Amsterdam University Medical Centers (Amsterdam UMC), highlighting new validation results using Foresight CLARITY MRD, along with a trial-in-progress poster on the SHORTEN-ctDNA clinical trial in partnership with Columbia University. Foresight CLARITY’s ultra-sensitive MRD detection is powered by Foresight’s proprietary PhasED-Seq technology, which delivers an analytical sensitivity of less than 1 part per million in B-cell lymphoma.1
"These presentations mark important clinical validation milestones for our Foresight CLARITY platform," said Dr. David Kurtz, Chief Medical Officer at Foresight Diagnostics. "The presentations demonstrate that our ultra-sensitive MRD detection at the end of first-line therapy identifies DLBCL patients at significantly higher risk of relapse. Meanwhile, the SHORTEN-ctDNA study is exploring how MRD testing can inform de-escalation strategies in newly diagnosed patients. Our goal is to provide oncologists with actionable data that meaningfully improves treatment decisions and patient outcomes."
Further information about the presentations is below:
Oral Presentation Details:
Title: Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial
Presenter: Steven Wang, MD, PhD (Amsterdam UMC)
Session: Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Time: Friday, May 30 | 2:45 – 5:45 p.m. CDT
Location: Room S100a or live stream for virtual attendees
Abstract number: 7000
Poster Presentation Details:
Title: Sequencing-guided Chemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA (NCT06693830)
Presenter: Stephanie Meek, PhD (Foresight Diagnostics)
Session: Poster Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Time: Sunday, June 1 | 9:00 a.m. – 12:00 p.m. CDT
Abstract number: TPS7096
Poster Board number: 272a
In addition, the Foresight Diagnostics booth is located in the Innovation Hub #3. To learn more about Foresight’s activities at ASCO (Free ASCO Whitepaper), please visit the ASCO (Free ASCO Whitepaper) event page on our website.